

上海美迪西生物医药股份有限公司

+86(21)58591500
+86(21)58596369

585

marketing@medicilon.com.cn
www.medicilon.com.cn
201299

• 01



01 2022
03 2022
05
13
19
31
47

48
53
62

• 54

65

69 2022
71 2021
74 2022
76
79
82
85
88 □





2020 4

“ ”

MAX

CRO

2022 9 7

“ ”
“ ”



&CEO

&CEO
&CEO

CRO 8.16

1710

268 IND



CFDA/NMPA

FDA

TGA

CRO+CDMO



CRO

AI

8000



AI

“ ” NDFC /
&CEO



2004

CRO



CEO

CSO

CEO
CSO&

10 VIC

&CEO
CEO

&CEO

VIC

CRO


VIC

2022 9 21

() “ ” “ ”

15.7 66.9

15





&CEO

150




&



CRO+CDMO

&



“ ”


2022

“First in class”“Best in class”
CRO+CDMO

“ ”
“ ”
“ ”
&CEO

CRO

”



2022年6月17日

2022年6月17日
“ ”
“ ”




“ ”
“ ”
“ ”

AI

2022年6月19日
“ ”
“ ”
AI

“ ”
KINET

AI
FIC/BIC



CEO
“ ”



AI

KINET

FIC/BIC

&CEO

&

IND

2022 6 23

IND

&CEO

GLP

CRO
IND

GLP

18
26

&CEO

&

4

IND



RNA

2022 6 24

Pharmaceuticals Inc.

RNA

RNA
RNA

ACON

1 mRNA

RNA

IND

RNA

siRNA mRNA

circular RNA

AAALAC

NMPA



IND

&CEO

RNA

4 siRNA

IND

2022 6 28

“ ”

CAV

HPV



CEO

CRO

”

“

”

ZY

2022 6 28

“ ” ZY Therapeutics Inc.
“ZY” IND



ZY

mRNA, RNAi DNA_

ZY

CRO

CAR-T TCR-T

CAR-NK AAV

ZY

ZY

&CEO

ZY

“

”

ZY

ZY &CEO Dr. Jian Bao

ZY

”

2022 9 20

“ ”
“ ”

CRO
IND-CMC
&
CRO
GMP CDMO
130+ CDMO
10+
CDMO
CRO

” “
GLP CMC

2022 11
“ ”
“ ”

PharmaMind TM AI+
—TopTar-
gets TM First-in-Class

&CEO
AI
AI+
AI

FDA GLP AAALAC NMPA GLP
TGA OECD GLP

18 PharmaMind TopTargets

268 IND
AI CRO 2022 6

“ ”
PharmaMind TopTargets



“ ” DXC007
 / AML
 DXC007 4 ADC “ ”
 4 ADC
 ADC

9年17条产品管线,多禧生物专注于ADC药物研发

2012 ADC 9 17
 2021 6 Muc1 ADC
 2021 9 DX126-262
 ADC IND
 9 ADC 29 PCT
 ADC

美迪西ADC临床前研发平台,淬炼经验再出发

ADC DXC007 SEND 4 ADC
 DXC007 ADC
 ICH S6 S9 DXC007
 NMPA FDA GLP
 ADC
 ADC ADC
 ADC ADC
 ADC
 best-in-class first-in-class ADC

LQ036

IL-4R () “ ” LQ036
 IND

成功助力LQ036制剂质量研究, 纳米抗体吸入制剂研发再破难题

LQ036 LQ036 NMPA TGA

LQ036

DPI Nasal Spray COPLEY

NGI COPLEY BRS2100 COPLEY

LQ036 LQ036

“ ”

4 **EP4** **YY001**

“ ” EP4 YY001

NMPA 1 YY001 GLP DRF

“ ” YY001 GLP DRF

填补领域空白, 中国原研首个靶向EP4的新药获批临床

YY001 EP4 EP4

2 4 5-10

YY001 PD-1 PD-1

美迪西临床前研究毒理研究部, 高质效助力全球新药毒理研究

CRO YY001

NMPA

ADC PO IV

GLP AAALAC NMPA GLP FDA GLP TGA OECD

GLP YY001 YY001

5 **FTE I** **IgG4-RD**

“ ” ScientiaClinical Research

CCR8 IPG7236 I

CCR8 IPG7236 “ ” FTE

CCR8拮抗剂IPG7236, 有望成为全球第一款治疗IgG4-RD的非甾体激素类药物

IgG4 IgG4-RD Mikulicz

2018 5 11 5

IgG4-RD CCR8 pDC CCR8

IPG7236 CCR8 IgG4-RD first-in-class 2021 8 12

FDA CDE

Stable Disease IPG7236 SMC

美迪西FTE团队, 为新药研发机构提供表现优质的苗头化合物

IPG7236 FTE CCR8

FTE

FTE

IPG7236 I IPG7236 IgG4-RD

6 **FR ADC** **BAT8006**

“ ” BAT8006

FR ADC “ ” ADC

ADC ADC ADC

9

CD19× CD3× CD28

FDA

FDA " " CD19/CD3/CD28 CC312 IND
 " " CD28
 " " CC312 GLP
CD19×CD3×CD28三特异性抗体, 在肿瘤免疫治疗领域探索新的可能性
 —TriTETM Tri-specific T-cell Engager
 T " "
 CC312 TriTETM WO2018120843A1 CC312 CD19 CD3
 CD28 scFv CC312 CD19 T CD3 CD28
 T T T T CD3

美迪西临床前研究平台, 一站式助力新药研发
 CC3126

10

BAT2022

" " BAT2022 BAT2022
 " " BAT202
 GLP
双特异性中和抗体药物注射用BAT2022, 有望成为抗击新冠肺炎的高效新药
 BAT2022
 EC50 30-160 pM BAT2022 omicron BA.2.12.1
 BAT2022 30 pM
 alpha, beta, gamma, delta, omicron
 BAT202
 & BAT2022
 GLP BAT2022
 BAT2022
 CRO " " mRNA
 &

11

1 CGT-9475

" " ALK CGT-9475
 FDA
 2022 6 NMPA
CGT-9475, 优质化与差异化开发
 SCLC NSCLC 80%-85% NSCLC 3%-7% ALK NSCLC
 NSCLC ALK ALK
 ALK ALK CGT-9475

CGT-9475 NSCLC ALK RET
CGT-9475 ALK

盛世泰科,以差异化研发创新破局

first in class FGFR/VEGFR CGT-1881 CXCR4 ALK CGT-6321 CGT-9475

美迪西一站式研发平台,全方位赋能新药研发加速跑

CGT-9475

CGT-9475

1+1>2

221 IND

1460
2021

CGT-9475

CGT-9475

12 1 TRK CG001419


2022 08 08 Cullgen " " TRK
CG001419 IND CG001419 First in class TRK ()

CG001419 GLP " " CRO PROTAC

睿跃生物CG001419,全球首创的TRK蛋白降解剂

CG001419 uSMITE™ PROTAC PROTAC TRK

CG001419 NTRK I NTRK NTRK NTRK



美迪西PROTAC技术平台,助力PROTAC新药临床前研发

PROTAC
PROTAC-POI PROTAC-POI PROTAC-POI
CG001419 uSMITE™ CG001419
PROTAC PROTAC PROTAC
CG001419 PROTAC

13 FGFR1-4 RG002

Biopharma RTK-RAS-MAPK " " pan-FGFR RG002 Ringene
" " RG002 FTE RG002

RG002有望为晚期恶性肿瘤带来全新治疗方案
凌达生物的源头创新实力可鉴

RG002 pan-FGFR
FGFR
RG002 FGFR

RG002

美迪西一站式生物医药临床前研发服务平台全方位赋能新药研发加速跑

RG002
RG002

18

1+1>2

RG002 RG002

14

CDE ZT002

“ ” ZT002

IND

ZT002

质肽生物司美格鲁肽注射液, 可降糖、减重、护心的GLP-1周制剂

-1 GLP-1

/

2

2

1

GLP-1

ZDF II

DIO

db/db II

质肽生物ZT002注射液, 有望成为全球首个每月给药一次的GLP1受体激动剂

ZT002 (QLLong) GLP-1
ZT002 GLP1

GLP1

2-3

ZT002

NMPA FDA TGA

ZT002

ZT002

美迪西新药临床研究注册申报(IND)服务平台, 解锁多国申报, 助力全球布局

ZT002 TGA

(QLLong)

TGA






RNA
ADME
PK



CRO
CRO

mRNA
mRNA
mRNA
LNP-mRNA
LNP-mRNA
mRNA
LNP
mRNA



/CEO
/CEO
CRO



siRNA
siRNA




mRNA
mRNA
mRNA
LNP

9 25
”
CAR-T



/CEO
Alnylam
RNA
siRNA
siRNA
siRNA
siRNA
siRNA

2022
”
20
”
&CEO



CART

“ 0 1”



&CEO



CAR-T



“ ” “ ”

“ ”

iPSC

DNA

CRIPR/Cas9

(NHEJ)

(HDR)

tBE transformer Base Editor

/



CEO

“

”

ALK1
 ALK1
 GT90009
 ALK1
 VEGF-A
 HCC
 ALK1
 PDTX
 CRLM PDTX



70% NK
 NK
 &
 NK
 2021



1"

CEO

CEO
 T-cell engager
 Claudin18.2
 Q-1802

HCAb
 antibodies, HCAb
 HCAb
 HCAb
 4-1bb
 IgG heavy-chain only
 Harbour HCAb
 4-1BB HBICE@
 B7H4x4-1BB HBICE@HBM7008

2"

.....
 CEO
 &

2022年第二届张江AI智药论坛



11 17 “ ” “ ” 2022 AI

AI

AI

AI

&CEO

AI

AI



AI



AI

“ AI ”

AI



&CEO

AI

PCC

AI

AI+CRO+

AI


AI

AI

AI



AI+ AI+ AI



AI
10

AI


2022

AI

2022

AI+

AI+



AI

AI

AI

AI

ISM001-055

Hermite®

MoleculePro

AI

aExtractor

AI

PROTAC

AI

CarbonAI™

AI

CarbonAI™

CarbonAI™

80%

AI Digital

AI

AI

AI
TopTargets

PharmaMind

AI

AI

PharmaMind

MolMiner

AI

AI

AI

Pharma.AI
ics

Chemistry42

PandaOm-

InClinico

8

AIHPC

QPCTL

IPF

ISM001-055

1

GPU/CPU

"

"

AI

AI

AI

CRO

AI

PaddleHelix

AI

AI

PaddleHelix

HelixGEM

10

AI

HelixFold & HelixFold -Single
mRNA

AI

"

"

AI

Her-

AI

mite

AI for Science


AI

AI

美迪西云讲堂

&

| | | | | |
|----|--------------------------|--------|--|---|
| 1 | QbD | 4月14日 | | |
| 2 | 指导原则+实践经验—如何成功开展吸入制剂的研发? | 4月28日 | | |
| 3 | | 5月7日 | | |
| 4 | IND & | 5月19日 | | |
| 5 | | 6月9日 | | |
| 6 | | 6月16日 | | |
| 7 | | 6月30日 | | |
| 8 | | 7月14日 | | |
| 9 | | 7月28日 | | |
| 10 | | 8月11日 | | |
| 11 | | 9月29日 | | |
| 12 | & | 10月27日 | | |
| 13 | | 12月1日 | | |
| 14 | QA GLP | 12月12日 | | & |



美迪西，十八岁正风华

2022 2 2 18 “ ”

73800 1 2400 1000

CRO CDMO.....

“ ”

18

“ ”

“ ” “ ” “ ” “ ” “ ” “ ”

“ ” “ ” “ ” “ ” “ ” “ ”

18

œ

“ ”

CRO

.....

“ ”

出征！美迪西驰援上海核酸检测队

“ ”

3 13

2
&CEO

24 PCR

“ ”

“ ”

“ ”



封控不停工--记持续奋战的美迪西科研人

3 27

“ ”



.....

, 6



EHS

.....

三项大奖花落美迪西！首届中国上市公司经纶奖重磅揭晓



“ ”

“ ”

()

IR

30+ 50+ 10

..... 850

“2021

MSCI A

美迪西荣获“2021中国年度最佳雇主上海50强”

“Hi ”2021

“ ” “2021

50 ”

“ ” “ ”

“ ”

/Mini MBA

“ ”

.....

2000 92%

&CEO “ ’2021

50 ’

”



美迪西荣膺2021药物创新济世奖“年度十大药物创新服务机构”

4 20 “2021 ”

“ ” “

”

“ ”

“ ”



AI
1460
221 IND
“ ” 18 “ ”

美迪西连续4年荣登2021年度“中国CXO（含CDMO）企业TOP20排行榜”

2022 7 12
TOP20 ”
2021 “ CXO CDMO
“ ” “ CXO
CDMO TOP20 ” 4
“ ”
R&D



2021 2440 65.57%
2021 2440 48.60%
2021
“ ”

美迪西荣膺"2022年科创板上市公司100强"

SMDC “2022 100 ”
“ ”
“2022 100 ”
4 11 100
CRO “ ”



AI2021
24.52 87.66% 85 NMPA
15 FDA TGA
11.67 75.28% 2.82
118.12% 2440 48.60% 7.40
6.69
2021

美迪西荣登2022中国生物医药产业价值榜“最具影响力CXO企业TOP20”

2022 8 4 2022
“ ”
CXO TOP20”
2022

“2022
CXO TOP20” 2021

“

美迪西荣登2022中国生物医药科技创新
价值榜 “最具影响力创新CXO企业”

美迪西获评“科创板上市公司价值30强”

“
”
“ ” “ 30 ”
“ ”
16

A
CRO
2022 “ CXO TOP20” “2022
100 ” “2022 100 ” “2022 100
”

PROTAC
AI
CRO 18
CDMO

美迪西当选上海上市公司协会理事单位

2022 11 10

“ ”

2011 5 5

“ ”

2022 12 9

“2022

• ”

“2022

”

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]


[Redacted]

[Redacted]



Proteovant
 / Proteovant would like to
 give awards recognizing outstanding performance
 on our projects in 2022
 PVT Team
 /

QUANTA
 / QUA greatly appreciate
 your team's dedication, especially those coming
 to work on weekends to help us meeing our
 timeline
 QUA Team
 / +



LeadingTac
 /
 006
 PCT
 LT team
 /

Kunquant
 / Such dedication demon-
 strated by you and your team, that makes our
 collaboration fruitful, is highly valued and appre-
 ciated, particular during the time when pandemic
 affected everyone while you and your team still
 made great efforts to strengthen our collabora-
 tion.
 KBI group
 /

PTC Therapeutics
 During the past several months, the NLR
 team led by Bin has done a great job to get building
 blocks synthesized, final compounds prepared, and
 chemistry developed. The team responded to
 challenges quickly and came up with ideas proac-
 tively. To recognize the outstanding contribution of
 the NLR team, we would like to send a PTC jacket
 to each of the team members (including you as the
 leader)
 PTC NLR team
 PTC

/ 2022
 /

2022

DMPK

Kumquat Biosciences Inc.
DMPK PK
DMPK SD

Acuitas Therapeutics Inc.
DMPK
monkey PK/PD
DMPK SD

()
DMPK PK
DMPK SD

DMPK ADME
DMPK SD

AlaMab Therapeutics CEO
2022.09.20 28
2022.10.16 11.01

CEO
2022.08.23
2022.11.22
2022.11.22 GLP-1

3 CRO



AstraZeneca

I just received some Her2 staining data back from the Calu-3, Calu-6, AN3CA, HCC1954, and BT474 models.... And here is the comment from our molecular pathologist

FFPE blocks received from Medicilon were higher quality than blocks from any other CRO thus far.

No presence of over/under fixation, processed well (no dry edges, frayed tissue), excessive necrosis, samples were all uniform size.

The her2 staining was beautiful, and I wanted to share the above comment

Thank you for your hard work and beautiful sections!

TCA TCA ()
2022 TCA
First in Class
! “ TCA ”

/Regor Therapeutic Group


You have done a great work in the past year to help Regor achieve our goals. In recognition of this, we'd like to present you a trophy to express our gratitude for your excellent work.


2022

2022 6 22

“

”







6 7

2022

PK

“ ”



“ ” ——

——Work Hard,

but Work Smart

8 30

CEO

8 30

CEO

CEO

CEO







CEO



—


“ ”





call







show time



HR





2022年是个很特别的日子，我和心爱的她有了自己的宝宝，有了自己完整的小家，日子也更幸福了；7月，新入职，希望自己努力工作，挣钱养家！

——小西

我和她在一起了，于2020年结婚，今年第一次两个人过七夕了——因为明年就是三个人啦！

——小朋

第一次正式见面就见面了，然后住进新家（那时候还只是同事）她给我买了一双40码的鞋，还送了我一件衣服，可是我的脚是35码的呀……

——小花

一封来自美迪西人的情书

七夕是牛郎织女相会的日子，我们的人生从两条平行线，在六年前交会于一点上，一个多月以前，是我们相识的日子。那时你生气勃发，大大咧咧的样子深深吸引着我，我们一起加班，通宵，当客服，一起散步，放空，吃凉皮。陪你搬家，陪你布置，我们像是两个与生俱来特别有默契的人。在一天夜晚，我们就着步，我悄悄地牵你的手，与你许下诺言，你轻轻一声呢，表明了你心意。我们手牵着手慢慢走，也许这就是爱情，热烈但平凡，神秘但简单，我相信爱情，相信我们一起携手共度余生。

——小通

我们一起去故宫，颐和园，天安门北京的各种胡同，我们逛街选择最便宜的交通工具，我超市买买最便宜的水果，那个时候我们都没有工作，我刚刚研究生毕业，你刚刚本科毕业，你说我和你在一起，我受委屈了，你决定回老家考研，我去上海工作，我们最后不知道为啥就分了，你说你昨天给我买了七夕礼物，我们今天就分手了，你让我在上海找个可以陪伴我的人忘了。

——小橙子



ta

“ UNO ”

OK



200



2023

/

